<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-301" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Propofol Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Secor</surname>
            <given-names>Tara</given-names>
          </name>
          <aff>UPMC Pinnacle Lititz</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Safadi</surname>
            <given-names>Anthony O.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gunderson</surname>
            <given-names>Seth</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tara Secor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Safadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Seth Gunderson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-301.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Propofol is a phenol derivative administered intravenously that is commonly used for sedation and in general anesthesia. The most common formulation of propofol is a lipophilic emulsion, which allows for rapid distribution into the tissues, including across the blood-brain barrier. It is commonly used for sedation in the intensive care unit (ICU) because it has a short duration of action and rapid clearance. It has dose-dependent effects, leading to higher blood pressure and heart rate changes at higher doses. The initial administration can cause pain at the injection site. Though propofol has a generally favorable profile as a sedative, administration of toxic doses can have harmful effects. Propofol infusion syndrome (PRIS) results from propofol toxicity. This activity reviews the presentation, evaluation, and management of propofol toxicity and stresses the role of an interprofessional team approach in caring for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the evaluation of a patient with propofol toxicity.</p></list-item><list-item><p>Evaluate the history and physical exam findings typically present in patients with propofol toxicity.</p></list-item><list-item><p>Determine&#x000a0;the treatment options for propofol toxicity.</p></list-item><list-item><p>Communicate&#x000a0;modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by propofol toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=301&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=301">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-301.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Propofol is a drug commonly used for sedation and the implementation of general anesthesia. It is a phenol derivative given as an intravenous drug. The most common formulation is in a lipophilic emulsion, allowing rapid distribution into the tissues, including across the blood-brain barrier. It is commonly used for sedation in the ICU because it has a short duration of action and rapid clearance. It has dose-dependent effects, leading to higher blood pressure and heart rate changes at higher doses. The initial administration can cause pain at the injection site. Though propofol has a generally favorable profile as a sedative, administering toxic doses can harm a patient&#x02019;s overall condition. Propofol infusion syndrome (PRIS) is the manifestation of propofol toxicity.<xref ref-type="bibr" rid="article-301.r1">[1]</xref></p>
      </sec>
      <sec id="article-301.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Propofol infusion syndrome usually presents in patients who have been administered propofol for an extended time at high doses. Based on published case reports, the odds of developing PRIS increase when propofol is administered for over 48 hours or at a rate of around 4 mg/kg/hr (67 mcg/kg/minute).<xref ref-type="bibr" rid="article-301.r2">[2]</xref></p>
        <p>Risk factors include severe illnesses such as sepsis, cerebral injury, airway infection, and poor oxygen perfusion. Other possible considerations that may play a role in PRIS are low carbohydrate levels, use of glucocorticoids, subclinical mitochondrial disease, and carnitine deficiency.<xref ref-type="bibr" rid="article-301.r2">[2]</xref></p>
      </sec>
      <sec id="article-301.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Pain on propofol injection usually occurs in younger patients from 20 to 40 years old. It is also more common in females and a peripheral IV site.<xref ref-type="bibr" rid="article-301.r3">[3]</xref>&#x000a0;When propofol infusion syndrome was first identified, the typical presentation was a pediatric patient in the ICU under sedation with high doses of propofol. With the reporting of more cases, the average age has increased to around 58 years old. Overall, the incidence of PRIS is 1.1% in those who receive propofol &#x000ad;&#x000ad; infusions. PRIS more commonly occurs in males than in females. Studies have varied the estimated mortality rate from 18 to 32%.<xref ref-type="bibr" rid="article-301.r4">[4]</xref><xref ref-type="bibr" rid="article-301.r2">[2]</xref><xref ref-type="bibr" rid="article-301.r5">[5]</xref></p>
      </sec>
      <sec id="article-301.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Initial pain from propofol injection occurs due to endothelial irritation. Studies show that propofol initiates a cascade that leads to neurogenic inflammation in the spinal dorsal horn, which can cause injection pain to last 10 to 20 seconds.<xref ref-type="bibr" rid="article-301.r3">[3]</xref></p>
        <p>When propofol reaches a toxic level, it uncouples oxidative phosphorylation in the mitochondrial electron transport chain. Propofol also inhibits carnitine palmitoyltransferase, which is a part of fatty acid metabolism. Fatty acid accumulation can lead to arrhythmias and poor energy availability. An imbalance of energy supply and demand can further lead to organ dysfunction throughout the body.<xref ref-type="bibr" rid="article-301.r6">[6]</xref><xref ref-type="bibr" rid="article-301.r4">[4]</xref><xref ref-type="bibr" rid="article-301.r7">[7]</xref></p>
      </sec>
      <sec id="article-301.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Studies on human skeletal muscles show that higher doses of propofol (10mcg/mL) can lead to microscopic changes affecting cell survival. Mitochondrial membranes were affected, which caused a decrease in electron transport chain capacity. Furthermore, propofol inhibited fatty acid oxidation, which may contribute to the lost spare electron transfer chain capacity.<xref ref-type="bibr" rid="article-301.r6">[6]</xref>&#x000a0;</p>
        <p>Biopsies of skeletal muscle from patients with known PRIS reveal disorganized myofibrils, sarcomeres, and necrotic reactions. Kidneys had myoglobin casts with acute tubular necrosis. Cardiac histology showed myofibril degeneration with acute inflammation.<xref ref-type="bibr" rid="article-301.r8">[8]</xref></p>
        <p>In animal models, histologic exams show a range of organ dysfunction. The liver revealed focal liver cell necrosis and steatosis. There was evidence of interstitial pneumonia and pulmonary edema in the lungs. Skeletal muscle biopsies had signs of muscle necrosis and rhabdomyolysis. Other findings included myocarditis, loss of urinary bladder epithelium, and cholangitis.<xref ref-type="bibr" rid="article-301.r7">[7]</xref></p>
      </sec>
      <sec id="article-301.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Because propofol administration is intravenous, injection pain is a common side effect of its administration. Patients often complain of burning upon injection, lasting up to 20 seconds.<xref ref-type="bibr" rid="article-301.r3">[3]</xref></p>
        <p>If propofol infusion syndrome is suspected, the patient will present with metabolic acidosis with elevated lactic acid. Cardiac derangements may include hypotension, bradycardia, right bundle branch block, cardiac arrhythmias, and asystole. ECG may show toxicity with a Brugada-like pattern and a convex ST-elevation in the suitable precordial leads. Musculoskeletal injury can occur in the form of rhabdomyolysis and myopathy. Other signs may reflect renal and hepatic abnormalities, such as oliguria or hepatomegaly. Urine has also been noted to have a red or green appearance.<xref ref-type="bibr" rid="article-301.r4">[4]</xref><xref ref-type="bibr" rid="article-301.r7">[7]</xref></p>
      </sec>
      <sec id="article-301.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinical evaluation of the patient is essential to look for signs of organ dysfunction, especially if the patient cannot vocalize any discomfort due to the propofol sedation &#x02014; signs such as dark urine from rhabdomyolysis or hepatomegaly. Monitoring lab values regularly upon initiating and during propofol infusion will be essential to ascertain any early signs of PRIS. Results may reflect multi-organ system dysfunction. Serum lab values can reveal a high anion gap metabolic acidosis, lactic acidosis, and lipemic plasma. Additionally, there may be elevated serum creatine kinase, serum myoglobin, serum urea, serum potassium, and liver enzymes. Hypertriglyceridemia is not unexpected due to the lipemic nature of the medication, which can lead to pancreatitis.<xref ref-type="bibr" rid="article-301.r2">[2]</xref></p>
        <p>It is critical to monitor closely for any cardiac abnormalities. Any hint of arrhythmias may be an early sign of toxicity, and further tests must occur. Patients should be on telemetry, and serial EKGs are a consideration. Bradycardia is often the first sign of heart irregularities.</p>
      </sec>
      <sec id="article-301.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Lidocaine has been used to reduce propofol injection pain. It is usable either mixed with the propofol or before propofol administration. Either technique has demonstrated effectiveness.<xref ref-type="bibr" rid="article-301.r9">[9]</xref></p>
        <p>Due to the severe progression of PRIS, clinicians must have a high degree of suspicion of the disease to treat it properly. The first step to prevent worsening conditions is to discontinue the propofol infusion. If the patient still requires sedation due to other factors, another class of sedative should be substituted. The patient should then be hemodynamically stabilized. In severe cases, patients may require advanced cardiorespiratory support such as extracorporeal membranous oxygenation (ECMO). Severe bradycardia may require cardiac pacing. Propofol can inhibit calcium channel blockers, thus making the heart resistant to catecholamine interventions.<xref ref-type="bibr" rid="article-301.r2">[2]</xref></p>
        <p>The following steps to treat PRIS involve resolving the derangements caused by propofol. Any electrolyte abnormalities need to be either replaced or reduced. Hyperkalemia is treatable with calcium, insulin, beta2 agonists, or K-binders. Metabolic acidosis often needs to be normalized with continuous renal replacement therapy (CRRT). CRRT, therapeutic plasma exchange, hemodialysis, and hemofiltration may help reduce propofol serum levels, metabolites, and elevated electrolytes. Additionally, carbohydrate substitution has been shown to support fat metabolism.<xref ref-type="bibr" rid="article-301.r10">[10]</xref><xref ref-type="bibr" rid="article-301.r11">[11]</xref></p>
      </sec>
      <sec id="article-301.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to the many manifestations of PRIS, clinicians need to discern whether the signs and symptoms presented by a patient are due to propofol or another pathophysiologic mechanism. If propofol infusions are overlooked, the patient&#x02019;s condition may be considered to result from other severe illnesses such as shock, sepsis, or renal disease. Other possibilities are congenital problems (i.e., Brugada Syndrome) or medications that may be concomitantly given. If propofol is being administered, PRIS must remain high on the differential.<xref ref-type="bibr" rid="article-301.r12">[12]</xref></p>
      </sec>
      <sec id="article-301.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>PRIS has a poor prognosis, especially if not identified early. As stated before, the mortality rate varies but is about 18 to 32%. Patients have an improved chance of survival if clinicians know the risks and the early signs of the syndrome.</p>
      </sec>
      <sec id="article-301.s12" sec-type="Complications">
        <title>Complications</title>
        <p>The primary concern with propofol toxicity is the development of fatal conditions. Hypertriglyceridemia can lead to pancreatitis. Metabolic acidosis can develop, leading to other derangements. Cardiac failure and rhabdomyolysis are significant concerns for propofol toxicity. If PRIS continues without any timely intervention, the condition can be fatal. Some complications correlate with complex multimodal treatment options.</p>
      </sec>
      <sec id="article-301.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>A complete patient history is necessary before starting a propofol infusion. Patients should be encouraged to share any pertinent information that may deter using propofol as a sedative agent. Any previous reactions with propofol or a known mitochondrial disease could clue clinicians into a high risk of adverse effects. If there is a concern that high doses of propofol would be required or a patient is at risk of toxicity, another sedative should be considered.</p>
      </sec>
      <sec id="article-301.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Propofol toxicity is primarily a healthcare professional&#x02019;s responsibility to recognize and manage. First and foremost, the patient must be an appropriate candidate for propofol administration. Second, education for the clinical team on the proper use of propofol is a requirement; this includes knowing the limits of safe infusion rates. Pharmacists can check that the correct medication formulation and concentration are ready. The propofol administration should be with pumps with defined maximum infusion limits. Nursing staff should never let rates exceed 4mg/kg/min. Regular physical examinations and workups of the patient&#x02019;s condition should be monitored. Close supervision of the patient is necessary. Dietitians may be helpful to the team in safely increasing carbohydrate load to help prevent propofol toxicity. If PRIS is suspected, the team must take quick action to stop the propofol&#x000a0;infusion and treat it accordingly. All these interprofessional personnel working together as a coordinated healthcare team can best ensure the safe use of propofol for procedures and reacting to PRIS if it does begin to manifest.</p>
      </sec>
      <sec id="article-301.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=301&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=301">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/propofol-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=301">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/301/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=301">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-301.s16">
        <title>References</title>
        <ref id="article-301.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKeage</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Propofol: a review of its use in intensive care sedation of adults.</article-title>
            <source>CNS Drugs</source>
            <year>2003</year>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>235</fpage>
            <page-range>235-72</page-range>
            <pub-id pub-id-type="pmid">12665397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mirrakhimov</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Voore</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Halytskyy</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Propofol infusion syndrome in adults: a clinical update.</article-title>
            <source>Crit Care Res Pract</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>260385</fpage>
            <pub-id pub-id-type="pmid">25954513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desousa</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Pain on propofol injection: Causes and remedies.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2016</year>
            <season>Nov-Dec</season>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>617</fpage>
            <page-range>617-623</page-range>
            <pub-id pub-id-type="pmid">28066096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kraj&#x0010d;ov&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Waldauf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>And&#x0011b;l</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Du&#x00161;ka</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports.</article-title>
            <source>Crit Care</source>
            <year>2015</year>
            <month>Nov</month>
            <day>12</day>
            <volume>19</volume>
            <fpage>398</fpage>
            <pub-id pub-id-type="pmid">26558513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roberts</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Barletta</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Schumaker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuper</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yogaratnam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Xamplas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gerlach</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Szumita</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Anger</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Arpino</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Voils</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Grgurich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruthazer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study.</article-title>
            <source>Crit Care</source>
            <year>2009</year>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>R169</fpage>
            <pub-id pub-id-type="pmid">19874582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kraj&#x0010d;ov&#x000e1;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f8;vsletten</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Waldauf</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fri&#x0010d;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elkalaf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Urban</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>And&#x0011b;l</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trnka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thoresen</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Du&#x00161;ka</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effects of Propofol on Cellular Bioenergetics in Human Skeletal Muscle Cells.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>46</volume>
            <issue>3</issue>
            <fpage>e206</fpage>
            <page-range>e206-e212</page-range>
            <pub-id pub-id-type="pmid">29240609</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fudickar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bein</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Propofol infusion syndrome: update of clinical manifestation and pathophysiology.</article-title>
            <source>Minerva Anestesiol</source>
            <year>2009</year>
            <month>May</month>
            <volume>75</volume>
            <issue>5</issue>
            <fpage>339</fpage>
            <page-range>339-44</page-range>
            <pub-id pub-id-type="pmid">19412155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stelow</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Johari</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Crosson</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Apple</surname>
                <given-names>FS</given-names>
              </name>
            </person-group>
            <article-title>Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings.</article-title>
            <source>Clin Chem</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-81</page-range>
            <pub-id pub-id-type="pmid">10759487</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Euasobhon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dej-Arkom</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siriussawakul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muangman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sriraj</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pattanittum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lumbiganon</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Lidocaine for reducing propofol-induced pain on induction of anaesthesia in adults.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Feb</month>
            <day>18</day>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>CD007874</fpage>
            <pub-id pub-id-type="pmid">26888026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honore</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Spapen</surname>
                <given-names>HD</given-names>
              </name>
            </person-group>
            <article-title>Propofol infusion syndrome: early blood purification to the rescue?</article-title>
            <source>Crit Care</source>
            <year>2016</year>
            <month>Jul</month>
            <day>04</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>197</fpage>
            <pub-id pub-id-type="pmid">27373928</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Weissman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sprung</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Rund</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange as treatment for propofol infusion syndrome.</article-title>
            <source>J Clin Apher</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>30</volume>
            <issue>5</issue>
            <fpage>311</fpage>
            <page-range>311-3</page-range>
            <pub-id pub-id-type="pmid">25619501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-301.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diaz</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Prabhakar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Urman</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Propofol infusion syndrome: a retrospective analysis at a level 1 trauma center.</article-title>
            <source>Crit Care Res Pract</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>346968</fpage>
            <pub-id pub-id-type="pmid">25580289</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
